A Prospective Study of Remestemcel-L, Ex-vivo Cultured Adult Human Mesenchymal Stromal Cells, for the Treatment of Pediatric Participants Who Have Failed to Respond to Steroid Treatment for Acute Graft-Versus-Host Disease (aGVHD)

NCT02336230 | Completed Phase 3 Results DMC FDA Drug

• 1 other identifier: MSB-GVHD001
• Study Type: interventional
• Target: 55
• Locations: 1 country
• Sites: 20

Brief Summary

The study plans to treat at least 60 pediatric participants, male and female, between the ages of 2 months and 17 years inclusive with aGVHD following allogeneic hematopoietic stem cell transplant (HSCT) that has failed to respond to treatment with systemic corticosteroid therapy. Participants may have Grades C and D aGVHD involving the skin, liver and/or gastrointestinal (GI) tract or Grade B aGVHD involving the liver and/or GI tract, with or without concomitant skin disease.

Conditions

Grade B aGVHD; Grade C aGVHD; Grade D aGVHD

Keywords

GVHD

Outcome Measures

Primary Outcomes (1)

• Overall Response Rate (ORR) at Day 28 Post Initiation of Therapy

  ORR was defined as the percentage of participants who had achieved overall response. Overall response was defined as complete response (CR) plus partial response (PR) as per aGVHD response criteria. CR was defined as resolution of aGVHD in all involved organs. PR was defined as organ improvement of at least 1 stage without worsening of any other organ.

  Day 28

Secondary Outcomes (5)

• Overall Survival (OS) Rate at Day 100 Post Initiation of Therapy

  Day 100

• OS Rate at Day 100 Post Initiation of Therapy, Stratified by Responder Status at Day 28

  Day 100

• OS Rate at Day 100 Post Initiation of Therapy, Stratified by Baseline aGVHD Grade

  Day 100

• OS Rate at Day 100 Post Initiation of Therapy, Stratified by Organ Involvement

  Day 100

• OR Rate at Day 56 and 100 Post Initiation of Therapy

  Day 56 and Day 100

Study Arms (1)

Remestemcel-L 2×10^6 MSCs/kg

EXPERIMENTAL

Participants were treated with intravenous (IV) remestemcel-L at a dose of 2×10\^6 mesenchymal stromal cells (MSCs)/kilogram (kg) actual body weight at Screening, twice per week, for each of 4 consecutive weeks (initial therapy) given at least 3 days apart and no more than 5 days apart for any infusion. Eligible participants received an additional once per week infusion, for each of 4 consecutive weeks (continued therapy) of remestemcel-L and twice per week infusions, for each of 4 consecutive weeks (aGVHD flare therapy) of remestemcel-L at the same initial therapy dose of 2×10\^6 MSCs/kg actual body weight at Screening.

Drug: remestemcel-L

Interventions

remestemcel-L DRUG

Participants were treated with IV remestemcel-L at a dose of 2 x 10\^6 MSC/kg (actual body weight at screening) twice per week for each of 4 consecutive weeks. Infusions were administered at least 3 days apart and no more than 5 days apart for any infusion.

Remestemcel-L 2×10^6 MSCs/kg

Eligibility Criteria

• Age: 2 Months - 17 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17)

You may qualify if:

• Participant is diagnosed with Grade B-D acute GVHD requiring corticosteroid systemic therapy. The participant may have Grade C or D aGVHD involving the skin, liver, and/or GI tract or may have Grade B aGVHD involving the liver and/or GI tract, with or without concomitant skin disease. Acute GVHD is defined as the presence of skin rash and/or persistent nausea, vomiting, and/or diarrhea and/or cholestasis presenting in a context in which aGVHD is likely to occur and where other etiologies such as drug rash, enteric infection, or hepatotoxic syndromes are unlikely or have been ruled out.
• Participant has failed to respond to steroid treatment, with failure to respond defined as any Grade B-D \[International Bone Marrow Transplant Registry (IBMTR) grading\] aGVHD that shows progression within 3 days, or no improvement within 7 days of consecutive treatment with 2 mg/kg/day methylprednisolone or equivalent.
• Participant must be able to be treated with remestemcel-L within 4 days of signing of informed consent.
• Participants who have had persistent GI GVHD manifested by diarrhea with stool volume \< 500 mL/kg/day (for participants \>50 kg) or \<30 mL/kg/day (for participants ≤50 kg). See GVHD Organ Severity Criteria (Table 2) for values in mL/m\^2. In the absence of nausea or vomiting, participants could have been considered to have Grade B GVHD if:
• other causes of diarrhea had been ruled out (eg, Clostridium difficile, adenovirus or cytomegalovirus \[CMV\] infection, or oral magnesium administration), and if
• the low stool volume reflected the effects of fasting, narcotics, or antidiarrheal medications.
• Participant must have adequate renal function as defined by a calculated creatinine clearance of \>30 mL/min per 1.73 m\^2. For participants 1 to 18 years of age, creatinine clearance is calculated using the Bedside Schwartz equation:
• Glomerular filtration rate (GFR, in mL/min per 1.73 m\^2) = (0.413 \* height \[cm\])/serum creatinine (mg/dL)
• For participants younger than 1 year of age, renal function is determined using the Schwartz equation adjusted for this age group:
• Creatinine clearance (mL/min per 1.73 m\^2= (height \[cm\] x 0.45)/ (serum creatinine \[mg/dL\]).
• Participant has a minimum Karnofsky/Lansky Performance Level of at least 30 at the time of study entry.
• Participant (or legal representative where appropriate) must be capable of providing written informed consent.
• Female participants of childbearing potential (≥10 years of age) are required to use a medically accepted method of contraception and to agree to continue use of this method for the duration of the study and for the follow-up time period. Acceptable methods of contraception include abstinence, barrier method with spermicide, intrauterine device (IUD), or steroidal contraceptive (oral, transdermal, implanted, and injected) in conjunction with a barrier method.
• Male participants with partners of childbearing potential must agree to use adequate contraception (barrier method or abstinence) during the study, including the follow-up time period.
• The participant must be willing and able to comply with study requirements, remain at the clinic, and return to the clinic for the follow-up evaluation during the study period, as specified in this protocol.

You may not qualify if:

• Participant has Grade B aGvHD with skin-only involvement.
• Participant has received any second line therapy to treat aGVHD prior to screening.
• Participant has received systemic agents other than steroids and prophylactic agents for primary treatment of aGVHD.
• Participant shows evidence of diffuse alveolar hemorrhage or other active pulmonary disease, which is likely to require more than 2L of oxygen via face mask, or an estimated fractional inspired oxygen concentration (FiO2) of 28% via other delivery methods in order to sustain an O2 saturation of 92%.
• Participant has any underlying or current medical or psychiatric condition that, in the opinion of the Investigator, would interfere with the evaluation of the participant including but not limited to uncontrolled infection, heart failure, or pulmonary hypertension.
• Participant has received any stem cell agents (other than hematopoietic graft) during study participation or within 30 days prior to study entry. Previous use of irradiated granulocytes within 30 days is permitted.
• Participant has received an HSCT transplant for a solid tumor disease.
• Participant has had prior treatment with mesenchymal stem cells (MSCs), including remestemcel-L.
• Participant shows evidence of severe (required treatment) hepatic veno-occlusive disease (VOD) or sinusoidal obstruction at screening.
• Participant had positive laboratory test results indicating infection with the human immunodeficiency virus (HIV) at any time and/or active hepatitis B or C virus infection within 3 months prior to screening.
• Participant shows evidence of encephalopathy, as defined by a change in mental status since the onset of aGVHD.
• Participant is a female who is pregnant, lactating, or is planning a pregnancy during study participation, or in the follow-up period.
• Participant currently being treated for a solid tumor malignancy.
• Participant has participated in any interventional clinical trial for an aGVHD therapeutic agent. However, in exceptional cases, experimental agents may have been administered to enrolled participants at the Investigator's discretion.
• Participant has participated or is currently participating in any autologous and allogeneic stem cell or gene therapy study for the treatment of aGVHD. Participants participating in investigative protocols aimed at modification of the transplant graft (such as T-cell depletion) or aimed at modification of the conditioning regimen are allowed in the study.

Sponsors & Collaborators

• Mesoblast, Inc.: lead
• Quintiles, Inc.: collaborator

Study Sites (20)

Children's Hospital Los Angeles

Los Angeles, California, 90027, United States

Location

Children's Hospital of Orange County

Orange, California, 92868, United States

Location

University of California at San Francisco

San Francisco, California, 94143, United States

Location

Children's Hospital Colorado Center for Cancer/Blood Disorders

Aurora, Colorado, 80045, United States

Location

Alfred I. DuPont Hospital for Children of the Nemours Foundation

Wilmington, Delaware, 19803, United States

Location

Miami Children's Research Institute

Miami, Florida, 33136, United States

Location

Ann & Robert H. Lurie Children's Hospital of Chicago

Chicago, Illinois, 60611, United States

Location

Children's Hospital of Michigan

Detroit, Michigan, 48201, United States

Location

University of Mississippi Medical Center

Jackson, Mississippi, 39216, United States

Location

Washington University

St Louis, Missouri, 63110, United States

Location

Columbia University Medical Center

New York, New York, 10032, United States

Location

Memorial Sloan Kettering Cancer Center

New York, New York, 10174, United States

Location

Albert Einstein College of Medicine

New York, New York, 10467, United States

Location

Duke University Medical Center

Durham, North Carolina, 27705, United States

Location

Oregon University

Portland, Oregon, 97239, United States

Location

Medical University of South Carolina

Charleston, South Carolina, 29425, United States

Location

Texas Transplant Institute

San Antonio, Texas, 78229, United States

Location

Virginia Commonwealth University

Richmond, Virginia, 23284, United States

Location

Fred Hutchinson Cancer Research

Seattle, Washington, 98109, United States

Location

Medical College of Wisconsin

Milwaukee, Wisconsin, 53226, United States

Location

Related Publications (1)

• Kurtzberg J, Abdel-Azim H, Carpenter P, Chaudhury S, Horn B, Mahadeo K, Nemecek E, Neudorf S, Prasad V, Prockop S, Quigg T, Satwani P, Cheng A, Burke E, Hayes J, Skerrett D; MSB-GVHD001/002 Study Group. A Phase 3, Single-Arm, Prospective Study of Remestemcel-L, Ex Vivo Culture-Expanded Adult Human Mesenchymal Stromal Cells for the Treatment of Pediatric Patients Who Failed to Respond to Steroid Treatment for Acute Graft-versus-Host Disease. Biol Blood Marrow Transplant. 2020 May;26(5):845-854. doi: 10.1016/j.bbmt.2020.01.018. Epub 2020 Feb 1.

  PMID: 32018062 DERIVED

MeSH Terms

Interventions

remestemcel-l

Results Point of Contact

• Title: Christopher James, VP Head of Clinical Operations
• Organization: Mesoblast, Inc.

Christopher.James@Mesoblast.com

212-880-2060

Study Officials

• Christopher James

  Mesoblast, Inc.

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 30, 2014
• First Posted: January 12, 2015
• Study Start: June 4, 2015
• Primary Completion: April 9, 2018
• Study Completion: April 9, 2018
• Last Updated: March 17, 2022
• Results First Posted: March 17, 2022

Record last verified: 2022-02

Data Sharing

• IPD Sharing: Will not share

Locations

US (20)